ClinicalTrials.gg
RecruitingNCT04467333PHLHRUpdated Apr 1, 2025

Giessen Pulmonary Hypertension in Lung Cancer Registry

An observational study in Pulmonary Hypertension Due to Lung Diseases and Hypoxia, sponsored by University of Giessen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by University of Giessen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Hypoxia with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Hypoxia · Germany.

Started
2020
with 1 other
Observational
5 of 35
1 open now
Registered
30th of 35
by date

Among the 35 studies in Hypoxia with a site in Germany, this one is one of 2 that started in 2020, is one of 5 observational ones, and was the 30th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

4 of the 35 studies in Hypoxia with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hypoxia with a site in Germany, or all of them as a file.
02

Study summary

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.

03

Conditions studied

  • Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Equivalent to the average of patients with lung cancer in Germany.

Inclusion criteria

  • Patient with lung cancer at the University of Giessen lung Cancer Center.

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Weeks
Patient registry
Yes

Groups and cohorts

  • All lung cancer patients

    There will not be an intervention.

    Other: All lung cancer patients.

Interventions

  • OtherAll lung cancer patients.

    There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.

06

What researchers measure

Primary outcomes

  1. Pulmonary function test measured via Spirometry.

    vital capacity, total lung capacity, forced expiratory volume in one second, functional vital capacity, diffusing capacity for carbon monoxide, arterial partial pressure of oxygen; all measured as % of predicted normal values.

    Time frame: 2 years

  2. sPAP values measured via Echocardiography.

    systolic pulmonary artery pressure (sPAP) measured in millimetre of mercury (mmHg).

    Time frame: 2 years

  3. Body mass index.

    weight and height will be combined to report BMI in kg/m\^2.

    Time frame: 2 years

  4. Overall Survival and Progression Free Survival measured in days.

    Overall Survival and Progression free survival in days will be determined by Kaplan-Meier Analysis .Measuared in (st) (time from diagnosis to death)

    Time frame: 2 years

  5. Measurements of the pulmonary artery diameter (PA) and ascending aorta (AA) diameter measured via computed tomography scan. PA and AA will be measured in millimeters.

    PA and AA will be combined to report the PA/AA quotient as indicator for pulmonary hypertension in all lung cancer patients. With a cut off value of ≥ 1 defining pulmonary hypertension.

    Time frame: 2 years

  6. 6 Minute Walk Test in meters.

    The 6 minute walk test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome.

    Time frame: 2 years

  7. Modified Medical Research Council Scale (mMRC).

    Scores on the mMRC reach from 0-4, with higher scores indicating greater dyspnea.

    Time frame: 2 years

  8. chronic obstructive pulmonary disease assessment test (CAT).

    Scores on the CAT reach from 0-40, with higher scores indicating greater dyspnea.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlohner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017 Nov 15;9(416):eaai9048. doi: 10.1126/scitranslmed.aai9048. PubMed 29141888 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jan 2026, 67 months after the start.

Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 67 months is above that.

Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2020
First posted
Jul 13, 2020
StartActual
Jun 29, 2020
Primary completionEst.
Jan 29, 2026
CompletionEst.
Jan 29, 2040
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04467333
Lead sponsor
University of Giessen
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Jun 29, 2020
Primary completion
Jan 29, 2026 (estimated)
Completion
Jan 29, 2040 (estimated)
Last update
Apr 1, 2025

Study contacts

Bastian Eul, MD
Contact
bastian.eul@innere.med.uni-giessen.de
(+49) 0641/985-42371
Michael John Cekay, MD
Contact
michael.cekay@innere.med.uni-giessen.de
Bastian Eul, MD
principal investigator · JLU Giessen
Khodr Tello, MD
principal investigator · JLU Giessen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion